According to federal records and congressional testimony, the OIG probe examined millions in DEA contracts Milgram awarded without competition — including $4.7 million for “strategic planning” to personal associates, $1.4 million to WilmerHale for a politically connected “review,” and nearly $400,000 to a New Jersey ally hired within weeks of her confirmation.br These revelations came as the agency was failing its most critical mandate: responding to the nation’s demand for medical cannabis research and reform.br “While DEA insiders cashed in on sweetheart contracts, patients were left suffering,” said Duane Boise, President & CEO of MMJ BioPharma Cultivation, a pharmaceutical company still waiting — after seven years — for DEA approval to grow cannabis for FDA clinical trials. “Milgram’s DEA spent more time rewarding friends than fulfilling its legal duty to advance medical science. It was a monument to incompetence and indifference.”br “Anne Milgram was the DEA Administrator who couldn’t overhaul anything,” said Duane Boise, CEO of MMJ BioPharma Cultivation. “She wasn’t proactive, didn’t enforce accountability, and refused to even meet with her own staff on critical issues. The DEA under Milgram didn’t evolve — it evaporated.